Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Pratt

Showing results (41-50 of 134) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|May 20, 2026
Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imagingAidan Haslam, Gulnaz Iqbal, Mark Drayson, et al.
British Journal of Haematology|June 28, 2017
Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survivalGraham McIlroy, Jemma Mytton, Felicity Evison, et al.
Cancer|July 25, 2006
The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemiaSebastian Francis, Mamatha Karanth, Guy Pratt, et al.
Leukemia & Lymphoma|December 3, 2005
The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chainsGuy Pratt, Graham P Mead, Keith R Godfrey, et al.
British Journal of Haematology|January 12, 2022
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineGuy Pratt, Dima El-Sharkawi, Jaimal Kothari, et al.
Transplantation|July 10, 2010
Chronic graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptidesHelen J Smith, Rajesh Hanvesakul, Matthew D Morgan, et al.
BMJ Open|March 25, 2021
MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemiaSarah Brown, Debbie Sherratt, Samantha Hinsley, et al.
Blood|June 12, 2010
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisisThet Thet Lin, Boitelo T Letsolo, Rhiannon E Jones, et al.
Leukemia & Lymphoma|January 7, 2016
Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survivalGuy Pratt, Peter Thomas, Nicola Marden, et al.
Contemporary Clinical Trials Communications|April 24, 2019
Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancersJim Murray, Guy Pratt, Abe Jacob, et al.
Pageof 14

Showing results (41-50 of 134) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|May 20, 2026
Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imagingAidan Haslam, Gulnaz Iqbal, Mark Drayson, et al.
British Journal of Haematology|June 28, 2017
Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survivalGraham McIlroy, Jemma Mytton, Felicity Evison, et al.
Cancer|July 25, 2006
The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemiaSebastian Francis, Mamatha Karanth, Guy Pratt, et al.
Leukemia & Lymphoma|December 3, 2005
The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chainsGuy Pratt, Graham P Mead, Keith R Godfrey, et al.
British Journal of Haematology|January 12, 2022
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineGuy Pratt, Dima El-Sharkawi, Jaimal Kothari, et al.
Transplantation|July 10, 2010
Chronic graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptidesHelen J Smith, Rajesh Hanvesakul, Matthew D Morgan, et al.
BMJ Open|March 25, 2021
MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemiaSarah Brown, Debbie Sherratt, Samantha Hinsley, et al.
Blood|June 12, 2010
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisisThet Thet Lin, Boitelo T Letsolo, Rhiannon E Jones, et al.
Leukemia & Lymphoma|January 7, 2016
Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survivalGuy Pratt, Peter Thomas, Nicola Marden, et al.
Contemporary Clinical Trials Communications|April 24, 2019
Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancersJim Murray, Guy Pratt, Abe Jacob, et al.
Pageof 14